New pill targets brain Cancer's weakness in early human trial
NCT ID NCT07464925
Summary
This is a first-in-human study to find a safe dose of an experimental oral drug called GLIX1 for adults with aggressive brain tumors (high-grade glioma or glioblastoma) that have returned or worsened after standard treatments. The main goal is to check the drug's safety and side effects in about 30 participants, who will take daily capsules. Researchers will also look for early signs that the drug might help control the cancer by causing DNA damage specifically in tumor cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Northwestern Medicine
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.